TW200616632A - Compounds modulating c-kit activity and uses therefor - Google Patents

Compounds modulating c-kit activity and uses therefor

Info

Publication number
TW200616632A
TW200616632A TW094120055A TW94120055A TW200616632A TW 200616632 A TW200616632 A TW 200616632A TW 094120055 A TW094120055 A TW 094120055A TW 94120055 A TW94120055 A TW 94120055A TW 200616632 A TW200616632 A TW 200616632A
Authority
TW
Taiwan
Prior art keywords
uses therefor
kit activity
compounds modulating
kit
compounds
Prior art date
Application number
TW094120055A
Other languages
English (en)
Inventor
Prabha N Ibrahim
Clarence R Hurt
Chao Zhang
Jia-Zhong Zhang
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of TW200616632A publication Critical patent/TW200616632A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW094120055A 2004-06-17 2005-06-16 Compounds modulating c-kit activity and uses therefor TW200616632A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58089804P 2004-06-17 2004-06-17
US68207605P 2005-05-17 2005-05-17
US68205805P 2005-05-17 2005-05-17

Publications (1)

Publication Number Publication Date
TW200616632A true TW200616632A (en) 2006-06-01

Family

ID=35262233

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094120055A TW200616632A (en) 2004-06-17 2005-06-16 Compounds modulating c-kit activity and uses therefor

Country Status (9)

Country Link
US (1) US20060058339A1 (zh)
EP (1) EP1755597A2 (zh)
JP (1) JP2008503473A (zh)
AU (1) AU2005265017A1 (zh)
CA (1) CA2570817A1 (zh)
PA (1) PA8637601A1 (zh)
SV (1) SV2005002148A (zh)
TW (1) TW200616632A (zh)
WO (2) WO2006009755A2 (zh)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1696920E (pt) 2003-12-19 2015-01-14 Plexxikon Inc Compostos e métodos para o desenvolvimento de moduladores de ret
KR101298967B1 (ko) 2004-03-30 2013-09-02 버텍스 파마슈티칼스 인코포레이티드 Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
MX2007014377A (es) * 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
PL1893612T3 (pl) * 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
RU2453548C2 (ru) 2006-01-17 2012-06-20 Вертекс Фармасьютикалз Инкорпорейтед Азаиндолы, полезные в качестве ингибиторов янус-киназ
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
CA2673736A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
AR064675A1 (es) 2006-12-21 2009-04-15 Vertex Pharma Derivados heterociclicos de pirrolo- [2,3-b] piridina, inhibidores de proteinquinasas plk, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos hiperproliferativos
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CN102112478A (zh) * 2008-06-10 2011-06-29 普莱希科公司 用于激酶调节的5h-吡咯[2，3-b]吡嗪衍生物和其适应症
FR2941948B1 (fr) * 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
NZ594398A (en) 2009-04-03 2014-03-28 Plexxikon Inc Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof
TWI483941B (zh) 2009-06-17 2015-05-11 Vertex Pharma 流感病毒複製之抑制劑
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
IN2012DN01983A (zh) 2009-08-24 2015-07-24 Ascepion Pharmaceuticals Inc
CA2780190C (en) * 2009-11-06 2020-05-05 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CN105906631A (zh) 2009-11-18 2016-08-31 普莱希科公司 用于激酶调节的化合物和方法及其适应症
MX2012007429A (es) 2009-12-23 2012-07-23 Plexxikon Inc Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma.
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US20120076797A1 (en) * 2010-07-14 2012-03-29 Butte Atul J Modulation of kit signaling and hematopoietic cell development by IL-4 receptor modulation
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
SG194847A1 (en) 2011-05-17 2013-12-30 Plexxikon Inc Kinase modulation and indications therefor
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CA2861010A1 (en) 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
MX2015002887A (es) 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
DK2935248T3 (en) 2012-12-21 2018-04-23 Plexxikon Inc RELATIONS AND PROCEDURE FOR CHINESE MODULATION AND INDICATIONS THEREOF
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
SMT201800650T1 (it) 2013-03-15 2019-01-11 Plexxikon Inc Composti eterociclici e loro impiego
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
JP6564771B2 (ja) 2013-07-11 2019-08-21 エイシア バイオサイエンシーズ インコーポレイテッド キナーゼ阻害剤としてのピリミジン誘導体
MX2016006200A (es) 2013-11-13 2016-08-08 Vertex Pharma Metodos para preparar inhibidores de la replicacion de virus de influenza.
SMT201900450T1 (it) 2013-11-13 2019-09-09 Vertex Pharma Inibitori della replicazione di virus dell’influenza
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3145543A4 (en) * 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
EP3194392B1 (en) 2014-09-15 2020-01-01 Plexxikon, Inc. Heterocyclic compounds and uses thereof
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2017015267A1 (en) * 2015-07-20 2017-01-26 Genzyme Corporation Colony stimulating factor-1 receptor (csf-1r) inhibitors
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA3129180A1 (en) 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN107949388B (zh) 2015-10-09 2021-10-26 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
WO2017100201A1 (en) 2015-12-07 2017-06-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA3017972C (en) 2016-03-16 2023-03-28 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
US10703757B2 (en) 2016-12-23 2020-07-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
WO2018175311A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
US11498922B2 (en) 2017-04-07 2022-11-15 ACEA Therapeutics, Inc. Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
CA3065120A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
MX2019014288A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Articulos de manufactura y metodos relacionados a toxicidad asociada con terapia celular.
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
MX2019015155A (es) 2017-06-29 2020-08-03 Juno Therapeutics Inc Modelo de raton para valorar toxicidades asociadas con inmunoterapias.
JP7170030B2 (ja) 2017-07-25 2022-11-11 プレキシコン インコーポレーテッド キナーゼを調節する化合物の製剤
MA50057A (fr) 2017-09-01 2020-07-08 Juno Therapeutics Inc Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
JP7675519B2 (ja) 2017-10-13 2025-05-13 オプナ バイオ ソシエテ アノニム キナーゼを調節するための化合物の固体形態
JP7175309B2 (ja) 2017-10-27 2022-11-18 プレキシコン インコーポレーテッド キナーゼを調節する化合物の製剤
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CA3094336A1 (en) 2018-03-20 2019-09-26 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
US12246057B2 (en) 2018-04-13 2025-03-11 Board Of Regents, The University Of Texas System Transmembrane stem cell factor (tm-SCF) lipid nanocarriers and methods of use thereof
DK3886875T3 (da) 2018-11-30 2024-07-29 Juno Therapeutics Inc Behandlingsfremgangsmåder under anvendelse af adoptiv celleterapi
CA3120363A1 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
US11168093B2 (en) 2018-12-21 2021-11-09 Celgene Corporation Thienopyridine inhibitors of RIPK2
CA3134937A1 (en) 2019-03-29 2020-10-08 Kowa Company, Ltd. Novel azaindole derivative
BR112022010310A2 (pt) 2019-12-06 2022-08-16 Juno Therapeutics Inc Métodos relacionados com a toxicidade e resposta associada com terapia celular para tratamento de malignidades de célula b
US11845723B2 (en) 2019-12-24 2023-12-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CN111233857B (zh) * 2020-01-16 2021-01-08 河南应用技术职业学院 一种连续化生产培西达替尼的合成方法
CR20220396A (es) 2020-02-14 2022-11-14 Jounce Therapeutics Inc Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
MX2022013597A (es) 2020-04-29 2023-03-22 Plexxikon Inc Sintesis de compuestos heterociclicos.
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc Diacylglyercol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367B2 (en) 2021-06-23 2025-04-10 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
JP2024545193A (ja) 2021-12-22 2024-12-05 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
EP4493554A1 (en) 2022-03-17 2025-01-22 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
AU2024259556A1 (en) 2023-04-21 2025-10-23 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1573212A (en) * 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
US4568649A (en) * 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4626513A (en) * 1983-11-10 1986-12-02 Massachusetts General Hospital Method and apparatus for ligand detection
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6054270A (en) * 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5527681A (en) * 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5632957A (en) * 1993-11-01 1997-05-27 Nanogen Molecular biological diagnostic systems including electrodes
FR2687402B1 (fr) * 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JPH05236997A (ja) * 1992-02-28 1993-09-17 Hitachi Ltd ポリヌクレオチド捕捉用チップ
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
DE69420394T2 (de) * 1993-03-01 2000-04-13 Merck Sharp & Dohme Ltd., Hoddesdon Pyrrolopyridinderivate als dopaminrezeptor liganden
NZ261593A (en) * 1993-03-01 1996-09-25 Merck Sharp & Dohme 3-piperazinylmethly-1h-indolopyridine derivatives and pharmaceutical compositions
US6045996A (en) * 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6468742B2 (en) * 1993-11-01 2002-10-22 Nanogen, Inc. Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
US5965452A (en) * 1996-07-09 1999-10-12 Nanogen, Inc. Multiplexed active biologic array
US5807522A (en) * 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
GB9420521D0 (en) * 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5830645A (en) * 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
GB2298199A (en) * 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
US5959098A (en) * 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US5856174A (en) * 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5747276A (en) * 1995-09-15 1998-05-05 The Scripps Research Institute Screening methods for the identification of novel antibiotics
US6022963A (en) * 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
US6013440A (en) * 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
AU6443498A (en) * 1997-03-07 1998-09-22 Tropix, Inc. Protease inhibtor assay
US6826296B2 (en) * 1997-07-25 2004-11-30 Affymetrix, Inc. Method and system for providing a probe array chip design database
ES2260157T3 (es) * 1997-09-11 2006-11-01 Bioventures, Inc., Metodo para ser dispositivos de alta densidad.
US6465178B2 (en) * 1997-09-30 2002-10-15 Surmodics, Inc. Target molecule attachment to surfaces
US6048695A (en) * 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6277628B1 (en) * 1998-10-02 2001-08-21 Incyte Genomics, Inc. Linear microarrays
US6277489B1 (en) * 1998-12-04 2001-08-21 The Regents Of The University Of California Support for high performance affinity chromatography and other uses
US6221653B1 (en) * 1999-04-27 2001-04-24 Agilent Technologies, Inc. Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids
US6653151B2 (en) * 1999-07-30 2003-11-25 Large Scale Proteomics Corporation Dry deposition of materials for microarrays using matrix displacement
US20010008765A1 (en) * 1999-12-06 2001-07-19 Fuji Photo Film Co., Ltd. DNA chip and reactive solid carrier
ES2245955T3 (es) * 1999-12-21 2006-02-01 Sugen, Inc. 7-aza-indolin-2-onas 4-sustituidas y su utilizacion como inhibidores de proteina-quinasa.
DK1255536T3 (da) * 1999-12-22 2006-10-30 Sugen Inc Indolinonderivater til modulation af c-kit-tyrosinproteinkinase
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US7696225B2 (en) * 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
PT1696920E (pt) * 2003-12-19 2015-01-14 Plexxikon Inc Compostos e métodos para o desenvolvimento de moduladores de ret
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
EP1755597A2 (en) 2007-02-28
WO2006009755A3 (en) 2006-04-20
US20060058339A1 (en) 2006-03-16
WO2006009797A1 (en) 2006-01-26
SV2005002148A (es) 2005-12-09
WO2006009755A2 (en) 2006-01-26
AU2005265017A1 (en) 2006-01-26
CA2570817A1 (en) 2006-01-26
PA8637601A1 (es) 2006-06-02
JP2008503473A (ja) 2008-02-07

Similar Documents

Publication Publication Date Title
TW200616632A (en) Compounds modulating c-kit activity and uses therefor
UY28970A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
WO2007013896A3 (en) Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
MY158447A (en) Compounds modulating c-fms and/or c-kit activity and uses thereof
MX2009006162A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
MX2009006700A (es) Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
DE60330181D1 (de) Actriib-fusionspolypeptide und verwendungen dafür
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
UA116187C2 (uk) ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
WO2006014678A3 (en) Compositions and methods of using angiopoietin-like 4 protein
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP2239262A3 (en) Fused ring heterocycle kinase modulators
BRPI0415210A (pt) compostos e composições como inibidores de proteìna cinase
WO2005020921A3 (en) C-kit modulators and methods of use
TW200633980A (en) Pyridones useful as inhibitors of kinases
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
MX2007004862A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
IL173916A0 (en) Thienopyrazoles
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
PT2185561E (pt) Derivados de 1,2,3,4-tetra-hidropirrolo(1,2-a)pirazina-6- carboxamidas e de 2,3,4,5-tetra-hidropirrolo(1,2-a)-diazepina-7- carboxamidas, sua preparação e sua aplicação em terapia
NO20042846L (no) Derivater av 5-(pyridin-3-yl)-1-azabicyklo[3.2.1]oktan, fremstilling derav og anvendelse av de samme som terapeutiske midler
WO2005041888A3 (en) Pyrimidin-4-one compounds, compositions and methods
UA93679C2 (en) Compounds modulating c-kit and c-fms activity and uses therefor